Patrick O'Neil to Double-Blind Method
This is a "connection" page, showing publications Patrick O'Neil has written about Double-Blind Method.
Connection Strength
0.614
-
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018 08 25; 392(10148):637-649.
Score: 0.118
-
Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 11; 19(11):1529-1536.
Score: 0.110
-
EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS. Endocr Pract. 2016 11; 22(11):1277-1287.
Score: 0.103
-
Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012 Jul; 20(7):1426-36.
Score: 0.076
-
Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002 Jul; 10(7):633-41.
Score: 0.039
-
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 04 13; 325(14):1403-1413.
Score: 0.036
-
Vitamin D Supplementation and Prevention of Type 2 Diabetes. N Engl J Med. 2019 08 08; 381(6):520-530.
Score: 0.031
-
Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care. 2018 08; 41(8):1590-1599.
Score: 0.029
-
Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity (Silver Spring). 2016 11; 24(11):2278-2288.
Score: 0.026
-
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011 Jan; 19(1):110-20.
Score: 0.017
-
Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring). 2007 Apr; 15(4):895-905.
Score: 0.013
-
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 1999 Jun; 69(6):1108-16.
Score: 0.008
-
Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull. 1993; 29(2):183-8.
Score: 0.005
-
Naltrexone and dysphoria: a double-blind placebo controlled trial. Biol Psychiatry. 1987 Jun; 22(6):710-6.
Score: 0.003